cutaneous T-cell lymphoma

October 12, 2017

Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants

News

A Phase 2 trial is currently enrolling participants to evaluate 4SC‘s investigational therapy resminostat as a maintenance therapy for advanced-stage cutaneous T-cell lymphoma (CTCL). The RESMAIN study (NCT02953301) is being conducted at about ... Read more

August 18, 2017

Adcetris Might Be Approved for CTCL by December, as FDA Reviews Marketing Application

News

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) required to bring Seattle Genetics’ Adcetris (brentuximab vedotin) to the market for the treatment ... Read more

June 21, 2017

Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients

News

Seattle Genetics is asking the U.S. Food and Drug Administration to approve Adcetris (brentuximab vedotin) for an expanded set of cutaneous T-cell lymphoma patients. The agency has yet to authorize Adcetris for CTCL. A supplemental Biologics ... Read more

May 26, 2017May 26, 2017

EU Gives Orphan Drug Status to MRG-106 for Treating T-cell Skin Lymphomas

News

The European Union has granted orphan drug status to miRagen Therapeutics’s MRG-106 for the treatment of cutaneous T-cell lymphoma (CTCL). The status is given to treatments for rare diseases. It accelerates the ... Read more

May 24, 2017

Innate to Present New Data from Therapy Candidate for Cutaneous T-Cell Lymphoma

News

The Phase 1 trial evaluating IPH4102 in patients with relapsed or refractory cutaneous T-cell lymphoma has completed its dose escalation part and is preparing to initiate its cohort expansion part. While ... Read more

May 5, 2017May 5, 2017

Mallinckrodt Marks 30 Years of Treating Skin Problems in CTCL Patients Using ECP

News

Extracorporeal photopheresis (ECP) therapy for palliative care of skin manifestations of cutaneous T-cell lymphoma (CTCL) was approved 30 years ago and remains an important therapeutic tool worldwide. Mallinckrodt, the world’s ... Read more

April 17, 2017April 17, 2017

Remetinostat Gel Twice a Day Leads to 40% Skin Lymphoma Response Rate, Study Shows

News

Remetinostat gel applied twice a day led to partial or complete responses in 40 percent of patients with skin lymphoma, according to a Phase 2 clinical trial. The trial of ... Read more

April 13, 2017April 13, 2017

Argenx Begins Phase 2 Trial of ARGX-110 for Cutaneous T-cell Lymphoma

News

A Phase 2 trial evaluating the anti-CD70 antibody ARGX-110 in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) has begun dosing participants, argenx announced. “We have previously observed evidence of ... Read more

October 28, 2016October 28, 2016

NORD Issues Guide to Promote Diagnosis, Treatment of Cutaneous T-Cell Lymphoma

News

The National Organization for Rare Disorders (NORD), an independent advocacy organization for patients and families affected by rare diseases, recently published its latest addition to the NORD’s Physician Guide series, the new NORD Physician ... Read more

August 3, 2016April 4, 2017

Adcetris Shows Promise in Treating Cutaneous T-Cell Lymphoma in Phase 3 Study

News

Adcetris may greatly benefit patients with cutaneous T-cell lymphoma (CTLC) who received prior systemic or radiation therapy, according to Phase 3 clinical trial results recently announced by Takeda Pharmaceutical Company and Seattle Genetics. The study met ... Read more